1h Free Analyst Time
In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Global Immunoglobulins Market ReportSpeak directly to the analyst to clarify any post sales queries you may have.
The global immunoglobulins market was valued at USD 13.59 billion in 2020 and is expected to reach USD 21.58 billion by 2026, growing at a CAGR of 8.01% during the forecast period.
The following factors are likely to contribute to the growth of the immunoglobulins market during the forecast period:
- impact of the use of IVIg during transplant
- self-sufficiency programs for plasma-derived medicinal products
- Fractionation Process, and immunoglobulins in homecare
- Recent regulatory approvals for immunoglobulin.
MARKET OVERVIEW
The pandemic has had and continues to have a major impact on the plasma derivatives industry. It contributed to the increase in the cost/liter of collected plasma due to the increased donor fees and increased incidence of a fixed cost of centers with respect to the lower volumes collected. The recent developments and the increasing scope of immunoglobulin products in treating numerous rare and autoimmune diseases have increased the growth rate for the immunoglobulin industry.
KEY HIGHLIGHTS
- The price of immunoglobulin increased by around 5% in Europe and by 6% in the US.
- With the increasing outcome of the fractionation and the challenge of plasma shortage, the technological and scientific developments in the field of plasma fractionation are expected to drive the market of immunoglobins.
- Immunoglobulins dominate the industry of plasma-derived products. This share is largely attributed to the increasing demand resulting from developed ways of diagnosing autoimmune diseases.
- The major challenge for the immunoglobulin industry is to maintain the balance between supply and demand. As the immunoglobulin products require blood plasma, the production value is limited by the quantity of plasma collected.
- Partnerships with the official plasma collection agencies of the country have propelled the growth of many vendors.
The study considers the immunoglobulins market present scenario and it's market dynamics for the period 2020-2026. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent ones operating in the market.
SEGMENTATION ANALYSIS
- Intravenous immunoglobulins (IVIG) are the most used form of immunoglobulin to manage autoimmune diseases and immunodeficiency. Since the proposed therapeutic use of immunoglobulins, it is being administered through the intravenous route, which provides maximum bioavailability and maximum efficacy.
- The market is led by primary immunodeficiency, which acquired 26.05% of the global immunoglobulins market in 2020. The symptoms of primary immunodeficiencies are frequent pneumonia, baronial infections, sinus infection, skin infections, meningitis, inflammation, low platelet count, etc.
- The largest immunoglobulins market share based on end-users is acquired by the hospital and clinic segment. The home care segment is expected to grow faster because of the increasing demand for home healthcare services.
Segmentation By Product
- Intravenous Immunoglobulin
- Subcutaneous Immunoglobulin
- Intramuscular Immunoglobulin
Segmentation By Application
- Primary Immunodeficiency
- Chronic Immune Deficiency Polyradiculoneuropathy
- Secondary Immunodeficiency
- Immune Thrombocytopenic Purpura
- Myasthenia Gravis
- Others
By End User
- Hospital & Clinic
- Homecare
GEOGRAPHICAL ANALYSIS
- North America acquired a 46.00% share of the global immunoglobulins market in 2020. This is attributed to many factors such as higher awareness towards personal health, a patient-centric healthcare system, advancements in healthcare, higher throughput of plasma collection centers, leading global vendors being native to the industry, etc.
- Europe is the second-largest market for immunoglobulin products because of its higher demand compared to other regions. The region has a higher awareness and highly regulated market, which enables safe blood and plasma collection practices.
- APAC is considered an emerging industry for immunoglobulin products, which are needed for treating autoimmune disorders. China is leading the APAC immunoglobulins market. The Chinese population has a higher awareness of blood donation and its possible use in manufacturing life-saving products.
By Geography
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- APAC
- China
- Japan
- India
- Australia
- South Korea
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- Turkey
VENDOR ANALYSIS
- The key players in the immunoglobulins industry are Takeda Pharmaceutical, CSL Limited, Grifols, S.A, Kendrion Biopharma, and Octapharma AG.
- The global immunoglobulins industry is dominated by mainly three vendors, CSL Limited, Takeda Pharmaceutical Company Limited, and Grifols S.A. They share a highly competitive environment, where each competes in terms of newer product launches and regulatory approval for those and existing products.
- For new vendors, emerging markets and low-resource countries are ideal markets, as they have a higher population and greater inclination towards donating blood or plasma in compensation.
Major Vendors
- Takeda Pharmaceutical Company Limited
- CSL Limited
- Grifols, S.A
- Kendrion Biopharma
- Octapharma AG.
Other Prominent Vendors
- China Biologic Products Holding, Inc.
- Biotest AG
- LFB S.A.
- ADMA Biologics, Inc.
- Omrix Biopharmaceuticals LTD
- Zydus Cadila
- Bharat Serums ANd Vaccines Limited
- Reliance Life Sciences
KEY QUESTIONS ANSWERED:
1. How Big is the Immunoglobulins Market?2. What are the key trends in the Immunoglobulins Market?
3. Which region accounted for the largest Immunoglobulins Market Share?
4. Who are the key players in the immunoglobulins market?
5. What are the factors driving the immunoglobulins market?
Table of Contents
1 Research Methodology2 Research Objectives3 Research Process6 Market at a Glance
4 Scope & Coverage
5 Report Assumptions & Caveats
7 Introduction
8 Market Opportunities & Trends
9 Market Growth Enablers
10 Market Growth Restraints
11 Market Landscape
12 Product
13 Application
14 End-User
15 Geography
16 North America
17 Europe
18 APAC
19 Latin America
20 Middle East & Africa
21 Competitive Landscape
22 Key Company Profiles
23 Other Prominent Vendors
24 Report Summary
25 Quantitative Summary
26 Appendix
List of Exhibits
List of Tables
Companies Mentioned
- Takeda Pharmaceutical Company Limited
- CSL Limited
- Grifols, S.A
- Kendrion Biopharma
- Octapharma AG.
- China Biologic Products Holding, Inc.
- Biotest AG
- LFB S.A.
- ADMA Biologics, Inc.
- Omrix Biopharmaceuticals LTD
- Zydus Cadila
- Bharat Serums ANd Vaccines Limited
- Reliance Life Sciences
Methodology
Our research comprises a mix of primary and secondary research. The secondary research sources that are typically referred to include, but are not limited to, company websites, annual reports, financial reports, company pipeline charts, broker reports, investor presentations and SEC filings, journals and conferences, internal proprietary databases, news articles, press releases, and webcasts specific to the companies operating in any given market.
Primary research involves email interactions with the industry participants across major geographies. The participants who typically take part in such a process include, but are not limited to, CEOs, VPs, business development managers, market intelligence managers, and national sales managers. We primarily rely on internal research work and internal databases that we have populated over the years. We cross-verify our secondary research findings with the primary respondents participating in the study.
LOADING...
